Skip to main content

Table 3 Known group validity testing: Effect sizes for the differences within the prostate cancer sample between subgroups formed on the basis of comorbidity status, age, education and marital status

From: International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer

  PCa survivors
Co-morbidities Age Education Marital status
0–1 comorbiditiesa 2 or more co-morbidities Younger than 70a 70–80 80 and older Universitya College and high school Primary school only Singlea Partner
SF36: Physical Functioning   −0.60   −0.72 −1.05   −0.39 −0.67   0.22
SF36: Role-Physical   −0.66   −0.66 −0.84   −0.43 −0.44   −0.07
SF36: Bodily Pain   −0.86   −0.32 −0.55   −0.50 −0.53   −0.03
SF36: General Health   −0.48   −0.42 −0.73   −0.42 −0.70   0.30
SF36: Vitality   −0.57   −0.40 −0.58   −0.54 −0.73   0.03
SF36: Social Functioning   −0.47   −0.30 −0.41   −0.38 −0.56   0.27
SF36: Role-Emotional   −0.44   −0.46 −0.61   −0.56 −0.58   0.25
SF36: Mental Health   −0.49   −0.29 −0.65   −0.47 −1.02   0.26
QLQ-C30: Global health status/QoL   −0.61   −0.51 −0.85   −0.51 −0.79   −0.01
QLQ-C30: Physical Function   −0.58   −0.68 −0.95   −0.34 −0.63   0.12
QLQ-C30: Role Function   −0.52   −0.50 −0.55   −0.31 −0.59   −0.05
QLQ-C30: Emotional Function   −0.51   −0.27 −0.35   −0.35 −1.01   0.27
QLQ-C30: Cognitive Function   −0.49   −0.41 −0.87   −0.30 −0.48   0.03
QLQ-C30: Social Function   −0.58   −0.15 −0.29   −0.19 −0.53   0.37
QLQ-C30: Fatigue   −0.57   −0.23 −0.25   −0.53 −0.86   0.02
QLQ-C30: Nausea / vomiting   −0.14   0.07 −0.27   −0.10 −0.55   0.21
QLQ-C30: Pain   −0.58   −0.34 −0.40   −0.32 −0.27   −0.08
QLQ-C30: Dyspnoea   −0.54   −0.30 −0.60   −0.16 −0.65   0.34
QLQ-C30: Insomnia   −0.34   −0.39 −0.43   −0.32 −0.50   0.20
QLQ-C30: Appetite loss   −0.05   −0.23 0.29   −0.14 −0.63   0.09
QLQ-C30: Constipation   −0.50   −0.03 −0.57   −0.05 −0.66   0.04
QLQ-C30: Diarrhoea   −0.23   0.32 0.75   −0.07 0.16   0.32
QLQ-C30: Financial problems   0.12   0.63 0.35   −0.16 −0.21   0.36
IOC: Appearance concerns   −0.46   −0.38 −0.18   −0.25 −0.94   0.35
IOC: Body change concerns   −0.55   −0.41 −0.18   −0.42 −0.55   0.09
IOC: Life interferences   −0.59   −0.16 −0.28   −0.54 −0.84   0.16
IOC: Worry   −0.46   0.03 0.05   −0.05 −0.41   0.19
IOC: Negative Impact Scale   −0.62   −0.19 −0.15   −0.35 −0.73   0.21
PR25: Sexual activity   −0.12   −0.32 −0.75   0.05 −0.18   0.38
PR25: Sexual functioning   −0.51   −0.63 −0.35   0.25 0.22   0.23
PR25: Urinary problems   −0.50   −0.37 −0.60   −0.47 −0.67   0.27
PR25: Incontinence aid problems   −0.36   −0.74 −0.27   −0.43 −0.71   −0.30
PR25: Bowel problems   −0.39   −0.30 −0.51   −0.02 −0.61   0.16
PR25: Treatment related symptoms   −0.34   −0.27 −0.51   −0.54 −0.44   −0.01
  1. Effect sizes are displayed in bold in those cases where the known groups differed significantly (p ≤ .05). A positive effect size reflects better HRQoL than the reference group, and a negative effect size reflects worse HRQoL than the reference group. areference group. PCa = prostate cancer